Evaluation and Application of a PET Tracer in Preclinical and Phase 1 Studies to Determine the Brain Biodistribution of Minzasolmin (UCB0599).
Alpha-synuclein
Brain distribution
Minzasolmin
PET tracers
PET-imaging
Parkinson’s disease
Phase 1 study
Journal
Molecular imaging and biology
ISSN: 1860-2002
Titre abrégé: Mol Imaging Biol
Pays: United States
ID NLM: 101125610
Informations de publication
Date de publication:
18 Dec 2023
18 Dec 2023
Historique:
received:
06
04
2023
accepted:
13
11
2023
revised:
25
10
2023
medline:
19
12
2023
pubmed:
19
12
2023
entrez:
19
12
2023
Statut:
aheadofprint
Résumé
Minzasolmin (UCB0599) is an orally administered, small molecule inhibitor of ASYN misfolding in development as a potential disease-modifying therapy for Parkinson's disease. Here we describe the preclinical development of a radiolabeled tracer and results from a phase 1 study using the tracer to investigate the brain distribution of minzasolmin. In the preclinical study, two radiolabeling positions were investigated on the S-enantiomer of minzasolmin (UCB2713): [ to determine biodistribution of minzasolmin in the human brain; secondary objectives included minzasolmin safety/tolerability. Preclinical data supported the use of [ Following positive preclinical results with the N-methyl labeled PET tracer, [
Identifiants
pubmed: 38110790
doi: 10.1007/s11307-023-01878-7
pii: 10.1007/s11307-023-01878-7
doi:
Banques de données
ClinicalTrials.gov
['NCT04875962']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Jankovic J, Tan EK (2020) Parkinson’s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 91:795–808
doi: 10.1136/jnnp-2019-322338
pubmed: 32576618
Simon DK, Tanner CM, Brundin P (2020) Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med 36:1–12
doi: 10.1016/j.cger.2019.08.002
pubmed: 31733690
Chen SW, Drakulic S, Deas E et al (2015) Structural characterization of toxic oligomers that are kinetically trapped during alpha-synuclein fibril formation. Proc Natl Acad Sci U S A 112:E1994–2003
Fanning S, Selkoe D, Dettmer U (2020) Parkinson’s disease: proteinopathy or lipidopathy? NPJ Parkinsons Dis 6:3
doi: 10.1038/s41531-019-0103-7
pubmed: 31909184
pmcid: 6941970
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840
doi: 10.1038/42166
pubmed: 9278044
Alam P, Bousset L, Melki R, Otzen DE (2019) Alpha-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. J Neurochem 150:522–534
doi: 10.1111/jnc.14808
pubmed: 31254394
Jenner P (2015) Treatment of the later stages of Parkinson’s disease - pharmacological approaches now and in the future. Transl Neurodegener 4:3
doi: 10.1186/2047-9158-4-3
pubmed: 25973178
pmcid: 4429454
Price DL, Khan A, Angers R et al (2023) In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease. NPJ Parkinsons Dis 9:114
Schwarz TC, Beier A, Ledolter K et al (2023) High-resolution structural information of membrane-bound alpha-synuclein provides insight into the MoA of the anti-Parkinson drug UCB0599. Proc Natl Acad Sci USA 120:e2201910120
Smit JW, Basile P, Prato MK et al (2022) Phase 1/1b studies of UCB0599, an oral inhibitor of alpha-synuclein misfolding, including a randomized study in Parkinson’s disease. Mov Disord 37:2045–2056
doi: 10.1002/mds.29170
pubmed: 35959805
pmcid: 9804489
Bergstrom M, Grahnen A, Langstrom B (2003) Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 59:357–366
doi: 10.1007/s00228-003-0643-x
pubmed: 12937873
Burt T, John CS, Ruckle JL, Vuong LT (2017) Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans - a practical guide. Expert Opin Drug Deliv 14:657–672
doi: 10.1080/17425247.2016.1227786
pubmed: 27564533
Lappin G, Garner RC (2003) Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2:233–240
doi: 10.1038/nrd1037
pubmed: 12612650
MedDRA (2017) What’s new, MedDRA version 20.1. https://admin.meddra.org/sites/default/files/guidance/file/whatsnew_20_1_english.pdf . Accessed 23 Feb 2023
Uppsala Monitoring Centre (2017) What’s new in WHODrug. https://who-umc.org/media/2971/whats-new-in-whodrug-2017.pdf . Accessed 23 Feb 2023
Johansen A, Hansen HD, Svarer C et al (2018) The importance of small polar radiometabolites in molecular neuroimaging: a PET study with [(11)C]Cimbi-36 labeled in two positions. J Cereb Blood Flow Metab 38:659–668
doi: 10.1177/0271678X17746179
pubmed: 29215308
Stefanis L (2012) Alpha-synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med 2:a009399
doi: 10.1101/cshperspect.a009399
pubmed: 22355802
pmcid: 3281589
Lang AE, Siderowf AD, Macklin EA et al (2022) Trial of cinpanemab in early Parkinson’s disease. N Engl J Med 387:408–420
doi: 10.1056/NEJMoa2203395
pubmed: 35921450
Pagano G, Taylor KI, Anzures-Cabrera J et al (2022) Trial of prasinezumab in early-stage Parkinson’s disease. N Engl J Med 387:421–432
doi: 10.1056/NEJMoa2202867
pubmed: 35921451
Whone A (2022) Monoclonal antibody therapy in Parkinson’s disease - The end? N Engl J Med 387:466–467
doi: 10.1056/NEJMe2207681
pubmed: 35921458